ClinicalTrials.gg
TerminatedNCT07100938Updated May 28, 2026

A Study Investigating the Efficacy and Safety of BGB-45035 Versus Placebo in Adults With Moderate to Severe Active Rheumatoid Arthritis

A Phase 2 interventional study of BGB-45035 and Placebo in Rheumatoid Arthritis, sponsored by BeiGene. Terminated at 29 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-28.

Sponsored by BeiGene · Phase 2, Interventional, and Treatment

Why this study was terminated
Sponsor has concluded that patients are unlikely to derive sufficient benefit from treatment with BGB-45035 to support continuation of the clinical development program due to unfavored benefit/risk profile.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
49
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 249 studies in Arthritis, Rheumatoid with a site in China — 63 open to participants now, 72 under way, 3 of them phase 3. Arthritis, Rheumatoid · China.

Enrollment
160th of 217
49 · median 134
Started
2025
with 34 others
Phase 2
34 of 249
8 open now
Registered
214th of 249
by date

Among the 249 studies in Arthritis, Rheumatoid with a site in China, this one is the 160th largest by enrollment of the 217 interventional ones that give a count, is one of 35 that started in 2025, is one of 34 in phase 2, and was the 214th registered.

Arthritis, Rheumatoid

3,336 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

63 of the 249 studies in Arthritis, Rheumatoid with a site in China are open now. Recruiting first, the newest first:

58 more — sign in →

All 63 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 249 studies in Arthritis, Rheumatoid with a site in China, or all of them as a file.
02

Study summary

This study aims to evaluate the efficacy of BGB-45035 in adults with moderate to severe active rheumatoid arthritis (RA) who have had an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) or biologic disease-modifying antirheumatic drugs (bDMARDs)/targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs).

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) Degrader
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with rheumatoid arthritis (RA) based on American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) criteria for at least 3 months prior to screening
  • Demonstrated an inadequate response to, or loss of response or intolerance to at least 1 conventional synthetic disease-modifying antirheumatic drug (csDMARD) (Hydroxychloroquine, methotrexate [MTX], leflunomide, or sulfasalazine) or 1 biologic disease-modifying antirheumatic drug (bDMARD)/targeted synthetic disease-modifying antirheumatic drug (tsDMARD) treatment
  • Must be on stable dose of one of the following permitted therapies for ≥ 4 weeks prior to screening and during the study: methotrexate between 7.5 mg to 25 mg/week, hydroxychloroquine up to 400 mg/day, leflunomide up to 20 mg/day, or sulfasalazine between 1000 mg/day to 3000 mg/day

Exclusion criteria

Exclusion Criteria:

  • Class IV RA based on American College of Rheumatology revised criteria for classification of functional status in rheumatoid arthritis
  • Patients with a history of cancer in the last 5 years before the Screening Visit, with the exception of adequately treated basal cell or squamous cell carcinoma of the skin
  • Have failed more than 2 b/tsDMARDs (eg, excluded if have failed 2 bDMARDs and 1 tsDMARD)
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
49 participants (actual)

Study arms

  • Experimental
    BGB-45035

    Participants will receive BGB-45035 orally for up to 12 weeks

    Drug: BGB-45035

  • Placebo comparator
    Placebo

    Participants will receive placebo orally for up to 12 weeks

    Drug: Placebo

Interventions

  • DrugBGB-45035

    Administered orally

  • DrugPlacebo

    Administered orally

06

What researchers measure

Primary outcomes

  1. Change from baseline in Disease Activity Score - C-reactive protein (DAS28-CRP) at Week 12

    The DAS28-CRP is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), high-sensitivity C-reactive protein (hsCRP in mg/L), and Patient's Global Assessment of Arthritis Pain (measured on a Visual Analog Scale \[VAS\] from 0 \[no pain\] to 100 \[worst possible pain\]). Scores on the DAS28-CRP range from 0 to approximately 10, where higher scores indicate more disease activity. A score greater than 5.1 indicates high disease activity, a score between 3.2 and 5.1 indicates moderate disease activity, a score between 2.6 and 3.2 indicates low disease activity, and a score less than 2.6 indicates the participant is in remission.

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Percentage of participants with a 20% improvement in American College of Rheumatology Criteria (ACR20)

    The ACR20 is defined as at least 20% improvement in the ACR core set values as defined below. Participants must meet 3 conditions for improvement from Baseline: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

    Time frame: Baseline and Week 12

  2. Percentage of participants with a 50% improvement in American College of Rheumatology Criteria (ACR50)

    The ACR50 is defined as at least 50% improvement in the ACR core set values as defined below. Participants must meet 3 conditions for improvement from Baseline: 1. ≥ 50% improvement in 68-tender joint count; 2. ≥ 50% improvement in 66-swollen joint count; and 3. ≥ 50% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

    Time frame: Baseline and Week 12

  3. Percentage of participants with a 70% improvement in American College of Rheumatology Criteria (ACR70)

    The ACR70 is defined as at least 70% improvement in the ACR core set values as defined below. Participants must meet 3 conditions for improvement from Baseline: 1. ≥ 70% improvement in 68-tender joint count; 2. ≥ 70% improvement in 66-swollen joint count; and 3. ≥ 70% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

    Time frame: Baseline and Week 12

  4. Change from Baseline in Tender Joint Count 68 (TJC 68)

    The TJC 68 is an assessment of tenderness or pain in 68 joints. Sixty-eight joints will be assessed for tenderness/pain by an independent, blinded assessor. The response to pressure/motion on each joint is assessed using the following scale: Present/Absent/Not Done/Not Applicable. A lower score indicates there is less pain or tenderness present, while a higher score indicates more pain or tenderness is present.

    Time frame: Baseline up to Week 12

  5. Change from baseline in Swollen Joint Count 66 (SJC 66)

    The SJC 66 is an assessment of swelling in 66 joints. Sixty-six joints will be assessed for swelling by an independent, blinded assessor. The swelling present in each joint is assessed using the following scale: Present/Absent/Not Done/Not Applicable. A lower score indicates there is less swelling present, while a higher score indicates more swelling is present.

    Time frame: Baseline up to Week 12

  6. Change from baseline in physician's global assessment of disease activity (PhGADA_VAS)

    The PhGADA\_VAS is a single item that asks the physician to assess the participant's current disease activity on a 0- to 100-mm visual analog scale (VAS), with anchors of 0 = "no disease activity" and 100 = "extremely active disease."

    Time frame: Baseline up to Week 12

  7. Change from baseline in Simplified Disease Activity Index (SDAI) score

    The simplified disease activity index (SDAI) is a composite measure that sums the total number of: * 28 tender joint counts, * 28 swollen joint counts, * Patient's Global Assessment of Disease Activity measured on a VAS from 0 to 10 where 0= lowest disease activity and 10 = highest; * Physician's Global Assessment of Disease Activity measured on a VAS from 0 to 10, where 0 = lowest disease activity and 10 = highest, and * C-reactive protein (CRP) in mg/dL. The SDAI score ranges from 0 to approximately 86 where lower scores indicate less disease activity.

    Time frame: Baseline up to Week 12

  8. Change from baseline in Clinical Disease Activity Index (CDAI) score

    The Clinical Disease Activity Index (CDAI) is a composite index that is calculated as the sum of the: * 28 tender joint count (TJC), * 28 swollen joint count (SJC), * Patient's Global Assessment of Disease Activity measured on a VAS from 0 to 10 where 0 = lowest disease activity and 10 = highest; * Physician's Global Assessment of Disease Activity (measured on a VAS from 0 to 10 where 0 = lowest disease activity and 10 = highest). The CDAI score ranges from 0 to 76 where lower scores indicate less disease activity.

    Time frame: Baseline up to Week 12

  9. Change from baseline of participant's global assessment of disease activity (PaGADA_VAS)

    The PaGADA\_VAS is a single item that asks the patient to rate the current severity of their disease activity on a 0- to 100-mm VAS, with anchors of 0 = "no disease activity" and 100 = "extremely active disease."

    Time frame: Baseline up to Week 12

  10. Change from baseline of Participant's global assessment of arthritis pain (VAS)

    The Participants's global assessment of arthritis pain (VAS) is a single item that asks the patient to rate the current severity of their pain in relation to their RA on a 0- to 100-mm VAS, with anchors of "no pain" and "worst possible pain."

    Time frame: Baseline up to Week 12

  11. Change from baseline of Participant's assessment of physical function as measured by the Health Assessment Questionnaire - Disability Index (HAQ-DI)

    The HAQ-DI is a patient-reported questionnaire that is commonly used in RA to measure disease-associated disability (assessment of physical function). Participants answer 24 questions using a scale from 0 to 3 to score difficulty when performing daily activities over the past week (0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, and 3 = unable to do). Scores on each task are averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three represents very severe, high-dependency disability.

    Time frame: Baseline up to Week 12

  12. Number of participants with adverse events (AEs)

    Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), including findings from laboratory tests

    Time frame: Up to approximately 4 months

07

Study locations

29 sites
  • The First Affiliated Hospital of Bengbu Medical University
    Bengbu, Anhui 233004, China
  • Anhui Provincial Hospital
    Hefei, Anhui 230000, China
  • Peking University First Hospital
    Beijing, Beijing Municipality 100034, China
  • Beijing Friendship Hospital, Capital Medical University
    Beijing, Beijing Municipality 100050, China
  • The Second Affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing Municipality 400010, China
  • Sun Yat Sen Memorial Hospital, Sun Yat Sen University (North)
    Guangzhou, Guangdong 510000, China
  • The First Affiliated Hospital, Sun Yat Sen University
    Guangzhou, Guangdong 510080, China
  • Nanfang Hospital, Southern Medical University
    Guangzhou, Guangdong 510515, China
  • The First Affiliated Hospital of Guangxi Medical University
    Nanning, Guangxi 530021, China
  • The Second Affiliated Hospital of Harbin Medical University
    Harbin, Heilongjiang 150001, China
  • The First Affiliated Hospital of Henan University of Science and Technology
    Luoyang, Henan 471003, China
  • Nanyang Central Hospital
    Nanyang, Henan 473000, China
  • Zhengzhou Central Hospital
    Zhengzhou, Henan 450007, China
  • The Second Xiangya Hospital of Central South University
    Changsha, Hunan 410011, China
  • Chenzhou No1 Peoples Hospital
    Chenzhou, Hunan 423000, China
  • The Affiliated Hospital of Inner Mongolia Medical University
    Hohhot, Inner Mongolia 010050, China
  • The First Peoples Hospital of Changzhou
    Changzhou, Jiangsu 213000, China
  • Nanjing Drum Tower Hospital,the Affiliated Hospital of Nanjing University Medical School
    Nanjing, Jiangsu 210008, China
  • Affiliated Hospital of Nantong University
    Nantong, Jiangsu 201203, China
  • Northern Jiangsu Peoples Hospital
    Yangzhou, Jiangsu 225001, China
  • The First Affiliated Hospital of Nanchang University Branch Donghu
    Nanchang, Jiangxi 330006, China
  • Pingxiang Peoples Hospital
    Pingxiang, Jiangxi 337055, China
  • The First Hospital of Jilin University
    Changchun, Jilin 130021, China
  • Affiliated Hospital of Liaoning University of Traditional Chinese Medicine
    Shenyang, Liaoning 110000, China
  • The First Affiliated Hospital of Xian Jiaotong University
    Xi'an, Shaanxi 710061, China
  • Huashan Hospital Fudan University
    Shanghai, Shanghai Municipality 200040, China
  • Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital
    Chengdu, Sichuan 610071, China
  • Affiliated Hospital of North Sichuan Medical College
    Nanchong, Sichuan 637000, China
  • The Second Affiliated Hospital of Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310009, China
08

References and documents

Individual participant data

Plan to share: Yes — BeiGene shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeiGene shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeiGene review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See plan description

Access criteria: See plan description

Data sharing details ↗ · beigene.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2025 to primary completion in May 2026, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2025
First posted
Aug 3, 2025
StartActual
Aug 21, 2025
Primary completionActual
May 12, 2026
CompletionActual
May 12, 2026
Last update
May 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07100938
Lead sponsor
BeiGene
Responsible party
Sponsor
First posted
Aug 3, 2025
Start date
Aug 21, 2025
Primary completion
May 12, 2026
Completion
May 12, 2026
Last update
May 28, 2026

Study contacts

Study Director
study director · BeiGene

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion